Fractional Medical Affairs Leadership

Why Biotech Does Not Need a Full-Time CMO to Move Fast

Most biotech companies reach the same inflection point around Series B or C. The science has advanced beyond what a skeleton crew can support, yet a full Medical Affairs department remains difficult to justify. Hire a Chief Medical Officer too early and you pay for scope that does not yet exist. Wait too long and KOL relationships, plus the scientific narrative, get built by committee or neglected entirely.

Fractional leadership closes this gap. It provides senior-level strategy from someone who has led MSL teams and developed publication plans, delivered at a scope and cost structure a growing company can support. The caliber of leadership matches what you would eventually hire full-time, but it is brought in while the narrative is still taking shape.

This model also flexes with the company's needs. Scale up for a data readout or launch

preparation, then scale back once the milestone passes. No permanent org chart is required. The companies that handle this transition do not wait until they can afford a full department. They bring in the right leadership early and allow it to mature into a permanent function only when the organization is truly ready.

The most efficient path is rarely the most obvious one. Companies that move fastest tend to partner with veterans who require no ramp-up, no internal selling, and no org-chart politics. Leaders who can assess the landscape in their first week and begin shaping the narrative in their second. When the timing is right, the transition to a permanent hire becomes a handoff rather than a scramble. Until then, the work simply needs to get done by someone who has done it before.

That is the work SciMedPro can accomplish for your organization: stepping in as a fractional Medical Affairs leader, building the scientific narrative and team, then scaling back as the company grows into its own full-time hire.